Trial Profile
A Double-blinded, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Topically Applied 1.0% WBI-1001 Cream for 12 Weeks, in the Treatment of Mild to Moderate Plaque Psoriasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2012
Price :
$35
*
At a glance
- Drugs Tapinarof (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 13 Apr 2011 Actual end date (1 Nov 2010) added as reported by ClinicalTrials.gov.
- 03 Feb 2011 Primary endpoint 'Physician's-Global-Assessment' has been met
- 03 Feb 2011 Status changed from active, no longer recruiting to completed.